Biotheryx

About:

Biotheryx is a clinical-stage biopharmaceutical company that focuses on the development of protein degrader therapies

Website: http://biotheryx.com

Top Investors: Alexandria Venture Investments, Lumira Ventures, Deep Track Capital, Wedbush Securities, Point72

Description:

Biotheryx is a clinical stage biopharmaceutical company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs) for the treatment of a wide range of diseases with an initial focus on cancer. Members of our founding and scientific teams previously developed the first FDA approved modulators of Cereblon, the most widely validated E3 ligase involved in protein degradation, and have applied their expertise in Cereblon binding to build our proprietary PRODEGY platform. Our platform leverages an extensive patent protected and rationally designed library of Cereblon binders that we believe provides us with a differentiated starting point for drug design of molecular glues, bifunctional degraders and hybrid degraders.